Literature DB >> 309731

Mechanisms of tumor immunity. An overview.

S Cohen, M C Cohen.   

Abstract

The involvement of the immune system in the host response to tumors is complex and involves both lymphocytes and lymphocyte-derived mediators, as well as inflammatory cells and various other agents such as complement. These activies are not confined to cytodestructive processes; recent studies demonstrate that the migration characteristics of tumor cells may be modified by immunologically derived substances. The multiplicity of possible immune system-neoplastic cell interaction is unfortunately balanced by the multiplicity of mechanisms that serve to interfere with an effective immune response to tumors. These mechanisms may reflect pathologic derangements of normal immunoregulatory processes or may involve the production of suppressive substances by the tumors themselves. In either case, a number of genetic and other predisposing factors must contribute to the ultimate resolution of the battle between host and tumor. Successful strategies for immunologic intervention must take these parameters into account.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 309731      PMCID: PMC2018370     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  20 in total

1.  An inhibitor of macrophage chemotaxis produced by neoplasms.

Authors:  R Snyderman; M C Pike
Journal:  Science       Date:  1976-04-23       Impact factor: 47.728

2.  Cytotoxicity in vitro by products of specifically stimulated spleen cells: susceptibility of tumor cells and normal cells.

Authors:  M S Meltzer; G L Bartlett
Journal:  J Natl Cancer Inst       Date:  1972-11       Impact factor: 13.506

Review 3.  Cytotoxic effects of lymphoid cells in vitro.

Authors:  P Perlmann; G Holm
Journal:  Adv Immunol       Date:  1969       Impact factor: 3.543

4.  Cytotoxicity of human lymphotoxin for tumor and normal human tissue cells in vitro.

Authors:  D D Weedon; L J DeMeester; L R Elveback; R G Shorter
Journal:  Mayo Clin Proc       Date:  1973-08       Impact factor: 7.616

5.  Migration-inhibiting effect of sera from patients with Burkitt's lymphoma.

Authors:  A J Cochran; G Klein; R Kiessling; P Gunvén
Journal:  J Natl Cancer Inst       Date:  1973-11       Impact factor: 13.506

6.  Human tumor cell migration.

Authors:  A J Cochran; R Kiessling; E Klein; P Gunvén; A K Foulis
Journal:  J Natl Cancer Inst       Date:  1973-10       Impact factor: 13.506

7.  Defective regulation of inflammatory mediators in Hodgkin's disease. Supernormal levels of chemotactic-factor inactivator.

Authors:  P A Ward; J L Berenberg
Journal:  N Engl J Med       Date:  1974-01-10       Impact factor: 91.245

8.  Macrophages activated as suspension cultures with lymphocyte mediators devoid of antigen become cytotoxic for tumor cells.

Authors:  W H Churchill; W F Piessens; C A Sulis; J R David
Journal:  J Immunol       Date:  1975-09       Impact factor: 5.422

9.  Structural changes produced in Brown-Pearce carcinoma cells by means of a specific antibody and complement.

Authors:  B KALFAYAN; J G KIDD
Journal:  J Exp Med       Date:  1953-01       Impact factor: 14.307

10.  The cytotoxic action of immune gamma globulin and complement on Krebs ascites tumor cells. II. Chemical studies.

Authors:  H GREEN; R A FLEISCHER; P BARROW; B GOLDBERG
Journal:  J Exp Med       Date:  1959-05-01       Impact factor: 14.307

View more
  2 in total

1.  Effect of interferon in therapy of skin and head and neck tumors.

Authors:  I Padovan; I Brodarec; D Ikić; M Knezević; E Soos
Journal:  J Cancer Res Clin Oncol       Date:  1981       Impact factor: 4.553

2.  Chitosan-based thermoreversible hydrogel as an in vitro tumor microenvironment for testing breast cancer therapies.

Authors:  Ching-Ting Tsao; Forrest M Kievit; Kui Wang; Ariane E Erickson; Richard G Ellenbogen; Miqin Zhang
Journal:  Mol Pharm       Date:  2014-05-15       Impact factor: 4.939

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.